Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNÎ³ secretion.

Chaganty, Bharat K R; Qiu, Songbo; Gest, Anneliese; Lu, Yang; Ivan, Cristina; Calin, George A; Weiner, Louis M; Fan, Zhen

Chaganty, Bharat K R; Qiu, Songbo; Gest, Anneliese; Lu, Yang; Ivan, Cristina; Calin, George A; Weiner, Louis M; Fan, Zhen.

Afiliación

Chaganty BKR; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
Qiu S; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gest A; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lu Y; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ivan C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Calin GA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
Weiner LM; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
Fan Z; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA. Electronic address: zfan@mdanderson.org.

Cancer Lett ; 430: 47-56, 2018 08 28.

Article en En | MEDLINE | ID: mdl-29746929

Asunto(s)

Antineoplásicos Inmunológicos/farmacología; Antígeno B7-H1/metabolismo; Neoplasias de la Mama/tratamiento farmacológico; Resistencia a Antineoplásicos/efectos de los fármacos; Receptor ErbB-2/metabolismo; Trastuzumab/farmacología; Animales; Antineoplásicos Inmunológicos/uso terapéutico; Antígeno B7-H1/antagonistas & inhibidores; Antígeno B7-H1/genética; Neoplasias de la Mama/genética; Neoplasias de la Mama/inmunología; Neoplasias de la Mama/patología; Técnicas de Cultivo de Célula; Línea Celular Tumoral; Técnicas de Cocultivo; Femenino; Regulación Neoplásica de la Expresión Génica/efectos de los fármacos; Técnicas de Silenciamiento del Gen; Humanos; Interferón gamma/antagonistas & inhibidores; Interferón gamma/inmunología; Interferón gamma/metabolismo; Leucocitos Mononucleares; Melanoma Experimental/tratamiento farmacológico; Melanoma Experimental/genética; Melanoma Experimental/inmunología; Melanoma Experimental/patología; Ratones; Ratones Endogámicos C57BL; Ratones Transgénicos; ARN Mensajero/metabolismo; Receptor ErbB-2/antagonistas & inhibidores; Receptor ErbB-2/genética; Transducción de Señal; Trastuzumab/uso terapéutico; Regulación hacia Arriba/efectos de los fármacos

Palabras clave

Breast cancer; HER2; IFNÎ³; PD-L1; Trastuzumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Resistencia a Antineoplásicos / Antígeno B7-H1 / Trastuzumab / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Lett Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google